| I-01 Annika Schneider Physiologically based pharmacokinetic modeling – application for renal and hepatic impairment Wednesday 10:10-11:40 |
| I-02 Johannes Schropp Characterization of bispecific antibodies and the ternary complex including an optimal dosing strategy Wednesday 10:10-11:40 |
| I-03 Pascal Schulthess Frequency-domain derived optimisation of cell cycle specific cancer treatment Wednesday 10:10-11:40 |
| I-04 Bernard Sebastien Hypoglycemic risk kinetics modeling as patient achieving glucose control in insulin-naïve T2DM patients initiating glargine 300U/mL versus glargine 100U/mL Wednesday 10:10-11:40 |
| I-05 Malte Selch Larsen Impact of trial designs, study conditions and statistical methods on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors Wednesday 10:10-11:40 |
| I-06 Jérémy Seurat Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes Wednesday 10:10-11:40 |
| I-07 Shringi Sharma A Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic Leukemia Wednesday 10:10-11:40 |
| I-08 Dmitry Shchelokov A semi-mechanistic model of targeted therapy for melanoma Wednesday 10:10-11:40 |
| I-09 Yucheng Sheng Item response theory modelling of motor scores to investigate feasibility of reducing proof-of-concept trial for Parkinson’s disease Wednesday 10:10-11:40 |
| I-10 Christian Siebel Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process Wednesday 10:10-11:40 |
| I-11 Alena Simalatsar Personalised delivery rate computation for intravenously administered anesthetic using Kalman filter Wednesday 10:10-11:40 |
| I-12 Erik Sjögren Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole Wednesday 10:10-11:40 |
| I-13 Mike K Smith Implementing “best practice” in Pop PK modeling Wednesday 10:10-11:40 |
| I-14 Tom Snowden A comparison of two model reduction methodologies for a QSP bone biology system with denosumab dosing. Wednesday 10:10-11:40 |
| I-15 Victor Sokolov Evaluation of the utility and efficiency of MATLAB and R-based packages for the development of quantitative systems pharmacology models Wednesday 10:10-11:40 |
| I-16 Eunjung Song Bayesian estimation of parameters in the pharmacokinetic model Wednesday 10:10-11:40 |
| I-17 Felix Stader A population database for elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parameters Wednesday 10:10-11:40 |
| I-18 Konstantinos Stamatopoulos A Population based PBPK Modelling for the Prediction of Bile Salts Disposition within GI Luminal Fluids – Towards a Mechanistic Bile Salts Model Wednesday 10:10-11:40 |
| I-19 Andrew Stein Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems Wednesday 10:10-11:40 |
| I-20 Mark Stroh Customizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology Wednesday 10:10-11:40 |
| I-21 Sabine Stuebler Systems biology model of the mucosal immune system in the context of inflammatory bowel disease Wednesday 10:10-11:40 |
| I-22 Claudia Suenderhauf The Basel Phenotyping Capsule as a tool for Quantifying Human metabolism in vivo – a tool to personalize physiological and semiphysiological Models Wednesday 10:10-11:40 |
| I-23 Elin Svensson Meta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trials Wednesday 10:10-11:40 |
| I-24 Robin Svensson The value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicin Wednesday 10:10-11:40 |
| I-25 Elisa Tacconi Model-based analysis for the screening and ranking of compounds against Plasmodium Falciparum Wednesday 10:10-11:40 |
| I-26 Chong Tang Population Pharmacokinetics of Tacrolimus in Pediatric Patients having undergone kidney, liver or bowel/liver transplantation. Wednesday 10:10-11:40 |
| I-27 Lénaïg Tanneau Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect Wednesday 10:10-11:40 |
| I-28 Sonya Chapman Dose Fractionation Study Design and PK/PD Model Analysis to Establish the Quantitative Pharmacology of Selective Aurora A Kinase Inhibition by Compound X and LY3295668 Wednesday 10:10-11:40 |
| I-29 Nadia Terranova The CICIL tool: a Java-based user-friendly application for the analysis of individual tumor size lesion dynamics Wednesday 10:10-11:40 |
| I-30 Adrien Tessier Population pharmacokinetics in adults and model-based extrapolation and dose selection in the paediatric DMD population for drug S48168/ARM210 Wednesday 10:10-11:40 |
| I-31 Mita Thapar Population pharmacokinetic and exposure-lymphocyte analysis of FTY720 (Fingolimod/Gilenya) in pediatric patients with Multiple Sclerosis Wednesday 10:10-11:40 |
| I-32 Pauline Themans Prediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approach Wednesday 10:10-11:40 |
| I-33 Tjokosela Tikiso TB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children Wednesday 10:10-11:40 |
| I-34 Tom Haber DiffMEM: an open-source package for high-performance pharmacometric model estimation Wednesday 10:10-11:40 |
| I-35 Elena Tosca In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone. Wednesday 10:10-11:40 |
| I-36 Kota Toshimoto Application of virtual clinical studies to predict the effect of inter-individual differences on the drug/metabolites exposures in the blood and target organs leading to different pharmacological and toxicological effect Wednesday 10:10-11:40 |
| I-37 Pauline Traynard New library of time-to-event (TTE) models for the MonolixSuite and application to two experimental data sets Wednesday 10:10-11:40 |
| I-38 Iñaki F. Trocóniz An immune quantitative framework for Hepatitis B viral infection Wednesday 10:10-11:40 |
| I-39 Denise Feick Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone Wednesday 10:10-11:40 |
| I-40 Sami Ullah Population pharmacokinetic analysis of piperacillin in acute haemorrhagic stroke patients - a cerebral microdialysis study Wednesday 10:10-11:40 |
| I-41 Chakradhara Rao Satyanarayana Uppugunduri Population pharmacokinetic model for individualized busulfan dosing in children: Annexation to the existing vast list of PopPK models for performance evaluation Wednesday 10:10-11:40 |
| I-42 Piet van der Graaf Systems pharmacology modelling of the alternative pathway to study target suitability Wednesday 10:10-11:40 |
| I-43 Louvina van der Laan Pharmacokinetics of intracellular stavudine-triphosphate in children after reduced-dose: can we improve stavudine’s safety profile? Wednesday 10:10-11:40 |
| I-44 Michiel Van Esdonk Population pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjects Wednesday 10:10-11:40 |
| I-45 Erno van Schaick Simulations of the paliperidone pharmacokinetics of intramuscular long-acting injectable microsuspensions of paliperidone palmitate in rats using a mechanistic model Wednesday 10:10-11:40 |
| I-46 Tamara van Steeg Development of a mathematical model to elucidate the cross-linking of GSK-057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality. Wednesday 10:10-11:40 |
| I-47 Rob van Wijk Nanoscale blood sampling from zebrafish larvae for the estimation of distribution volume and absolute clearance Wednesday 10:10-11:40 |
| I-48 Marc Vandemeulebroecke Graphical Principles Cheat Sheet Wednesday 10:10-11:40 |
| I-49 Diego Vera Disease modelling of repeated acute attacks in an acute intermittent porphyria mouse model Wednesday 10:10-11:40 |
| I-50 Swantje Völler Use of second-to-second physiological monitoring data for continuous evaluation of pharmacotherapy in preterm infants: an application to the respiratory stimulant doxapram Wednesday 10:10-11:40 |
| I-51 Veronika Voronova Using a physiologically-based QSP model to simulate the effects of perturbations of the enterohepatic circulation of bile acids Wednesday 10:10-11:40 |
| I-52 Johan Wallin Validation of Xenograft Dose Predictions for Clinical Efficacy in NSCLC Wednesday 10:10-11:40 |
| I-53 Evan Wang Model-based assessment of QT interval correction methods Wednesday 10:10-11:40 |
| I-54 Shijun Wang A comparison between nonlinear mixed effects and naïve pooled data methods in population PK model selection Wednesday 10:10-11:40 |
| I-55 Roeland Wasmann Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies Wednesday 10:10-11:40 |
| I-56 Sebastian Weber Supporting drug development as a Bayesian in due time?! Wednesday 10:10-11:40 |
| I-57 Sebastian Wicha Handling inter-occasion variability in model implementation for Bayesian forecasting: A comparison of methods and metrics. Wednesday 10:10-11:40 |
| I-58 Mélanie Wilbaux Risk score based on survival multivariate analysis of baseline patients’ characteristics reduces variability in a PKPD model of tumor growth inhibition Wednesday 10:10-11:40 |
| I-59 Justin Wilkins Population pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer types Wednesday 10:10-11:40 |
| I-60 Francis Williams Ojara A time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy Wednesday 10:10-11:40 |
| I-61 Dan Wright Identifying systematic bias in model predictions Wednesday 10:10-11:40 |
| I-62 Liviawati Wu Population Pharmacokinetics and Dosing Simulation of JNJ-64155806 (AL-794) in Healthy Volunteers Wednesday 10:10-11:40 |
| I-63 Gudrun Wuerthwein Population pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivity Wednesday 10:10-11:40 |
| I-64 Xia Li Population pharmacokinetics of ciprofloxacin in critically ill patients-a covariate analysis Wednesday 10:10-11:40 |
| I-65 Feifan Xie A model-based analysis of the kinetics of leukocytes in stage III ovarian cancer patients treated with neo-adjuvant chemotherapy, cytoreductive surgery and cisplatin-based intraperitoneal chemoperfusion Wednesday 10:10-11:40 |
| I-66 James Yates Structural Identifiability for Mathematical Pharmacology: Models of myelosuppression Wednesday 10:10-11:40 |
| I-67 Jinqiu Yin Optimizing treatment of cephalosporin-resistant pneumococcal meningitis Wednesday 10:10-11:40 |
| I-68 Gunnar Yngman Linearization of full random effects modeling (FREM) for time-efficient automatic covariate assessment Wednesday 10:10-11:40 |
| I-69 Jurij Aguiar Zdovc The expression of ABCB1 gene influences the PK of rivaroxaban – a PK/PD study in patients with the total hip or knee arthroplasty Wednesday 10:10-11:40 |
| I-70 Nan Zhang Creation of Pharmacometric Framework to Evaluate Clinical Trial Data on Predictive Biomarkers Wednesday 10:10-11:40 |
| I-71 Ying Zhang Exposure–Response Model and Development of a Shiny App of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients with Hereditary Angioedema (HAE) Wednesday 10:10-11:40 |
| I-72 Fan Zhang Structural and Practical Considerations in the Development of a Parent-metabolite Model Wednesday 10:10-11:40 |
| I-73 Xiaoyan Zhang Population pharmacokinetic/pharmacodynamic modeling of plasma lyso-sphingomyelin response to enzyme replacement therapy olipudase alfa in patients with acid sphingomyelinase deficiency Wednesday 10:10-11:40 |
| I-74 Li Zhang Mechanism-based Population PK/PD modeling of T lymphocytes Depletion and Repopulation Following Treatment with anti-CD52 Antibody GLD52 in Patients with Progressive Multiple Sclerosis Wednesday 10:10-11:40 |
| I-75 Chenyan Zhao Quantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae Wednesday 10:10-11:40 |
| I-76 Meng Zhaoling Real World Evidence and Model-informed Drug Development – an antidiabetic drug cardiovascular outcome case study Wednesday 10:10-11:40 |
| I-77 Yi Zheng Effect of pregnancy on raltegravir free concentrations Wednesday 10:10-11:40 |
| I-78 Xiao Zhu Application of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptor Wednesday 10:10-11:40 |
